Published in J Immunol on April 15, 2009
Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol (2011) 2.21
Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol (2009) 2.17
Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology (2012) 1.91
Distinct and overlapping effector functions of expanded human CD4+, CD8α+ and CD4-CD8α- invariant natural killer T cells. PLoS One (2011) 1.14
Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin Immunol (2010) 1.04
Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. Mol Immunol (2013) 1.02
The regulatory role of invariant NKT cells in tumor immunity. Cancer Immunol Res (2015) 0.96
The split personality of NKT cells in malignancy, autoimmune and allergic disorders. Immunotherapy (2011) 0.95
Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin Immunol (2011) 0.95
Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders. Blood (2009) 0.94
Α-galactosylceramide analogs with weak agonist activity for human iNKT cells define new candidate anti-inflammatory agents. PLoS One (2010) 0.93
Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma. PLoS One (2012) 0.91
Preferential depletion of gut CD4-expressing iNKT cells contributes to systemic immune activation in HIV-1 infection. Mucosal Immunol (2012) 0.91
NKT cell subsets as key participants in liver physiology and pathology. Cell Mol Immunol (2016) 0.86
Invariant NKT cells as novel targets for immunotherapy in solid tumors. Clin Dev Immunol (2012) 0.86
Lower numbers of circulating Natural Killer T (NK T) cells in individuals with human T lymphotropic virus type 1 (HTLV-1) associated neurological disease. Clin Exp Immunol (2009) 0.86
Immunology of hepatocellular carcinoma. World J Hepatol (2015) 0.83
Combination of intratumoral invariant natural killer T cells and interferon-gamma is associated with prognosis of hepatocellular carcinoma after curative resection. PLoS One (2013) 0.82
Regulation of NKT Cell Localization in Homeostasis and Infection. Front Immunol (2015) 0.81
Lipid antigens in immunity. Biol Chem (2014) 0.79
CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. Cancer Immunol Immunother (2012) 0.78
NKT cells act through third party bone marrow-derived cells to suppress NK cell activity in the liver and exacerbate hepatic melanoma metastases. Int J Cancer (2015) 0.77
Antitumor Responses of Invariant Natural Killer T Cells. J Immunol Res (2015) 0.75
Research highlights: Immunotherapy. Immunotherapy (2009) 0.75
Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma. Clin Exp Immunol (2010) 0.75
Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy. Transl Res (2017) 0.75
The Pathway Tools software. Bioinformatics (2002) 14.89
Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell (2008) 11.53
TLR3 deficiency in patients with herpes simplex encephalitis. Science (2007) 5.86
c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev (2004) 5.83
Flexible nets. The roles of intrinsic disorder in protein interaction networks. FEBS J (2005) 5.36
The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol (2008) 4.15
Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity (2011) 3.97
A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med (2011) 3.60
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 3.59
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest (2005) 3.11
Notch signaling in the immune system. Immunity (2010) 3.00
Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94
Coupled folding and binding with alpha-helix-forming molecular recognition elements. Biochemistry (2005) 2.94
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood (2002) 2.88
The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat Immunol (2008) 2.87
Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci U S A (2005) 2.83
Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest (2007) 2.80
The unfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics (2008) 2.72
Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Mol Microbiol (2004) 2.67
Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol (2007) 2.59
Lipid length controls antigen entry into endosomal and nonendosomal pathways for CD1b presentation. Nat Immunol (2002) 2.54
Recognition of β-linked self glycolipids mediated by natural killer T cell antigen receptors. Nat Immunol (2011) 2.42
Mycobacterium tuberculosis nuoG is a virulence gene that inhibits apoptosis of infected host cells. PLoS Pathog (2007) 2.36
Delta-like 4 is the essential, nonredundant ligand for Notch1 during thymic T cell lineage commitment. J Exp Med (2008) 2.17
Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum (2008) 2.15
Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A (2010) 2.12
Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice. Vaccine (2009) 2.12
A molecular basis for the exquisite CD1d-restricted antigen specificity and functional responses of natural killer T cells. Immunity (2011) 2.11
Mycobacterium tuberculosis controls host innate immune activation through cyclopropane modification of a glycolipid effector molecule. J Exp Med (2005) 2.10
A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog (2009) 2.09
Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. Crit Care (2012) 2.07
Simultaneous loss of beta- and gamma-catenin does not perturb hematopoiesis or lymphopoiesis. Blood (2007) 2.06
Portal vein embolization: what do we know? Cardiovasc Intervent Radiol (2011) 2.02
Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity (2009) 2.00
Mycobacterium tuberculosis pks12 produces a novel polyketide presented by CD1c to T cells. J Exp Med (2004) 1.96
Mining alpha-helix-forming molecular recognition features with cross species sequence alignments. Biochemistry (2007) 1.93
Intracellular pathways of CD1 antigen presentation. Nat Rev Immunol (2003) 1.91
EDEM3, a soluble EDEM homolog, enhances glycoprotein endoplasmic reticulum-associated degradation and mannose trimming. J Biol Chem (2006) 1.91
Dormant and self-renewing hematopoietic stem cells and their niches. Ann N Y Acad Sci (2007) 1.89
Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. J Clin Invest (2004) 1.89
Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol Oncol (2007) 1.88
Saposin C is required for lipid presentation by human CD1b. Nat Immunol (2004) 1.88
Adaptability of the semi-invariant natural killer T-cell receptor towards structurally diverse CD1d-restricted ligands. EMBO J (2009) 1.88
Deletion of kasB in Mycobacterium tuberculosis causes loss of acid-fastness and subclinical latent tuberculosis in immunocompetent mice. Proc Natl Acad Sci U S A (2007) 1.86
Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84
A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J Exp Med (2004) 1.81
Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression. Eur J Immunol (2009) 1.81
Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity (2005) 1.81
Mechanisms for glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells. J Immunol (2009) 1.81
Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2-dependent manner in mice. J Clin Invest (2011) 1.80
Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood (2003) 1.78
Human CD1-restricted T cell recognition of lipids from pollens. J Exp Med (2005) 1.78
Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One (2012) 1.77
D²P²: database of disordered protein predictions. Nucleic Acids Res (2012) 1.75
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol (2006) 1.74
Hierarchy of Notch-Delta interactions promoting T cell lineage commitment and maturation. J Exp Med (2007) 1.73
Mast cells are critical mediators of vaccine-induced Helicobacter clearance in the mouse model. Gastroenterology (2005) 1.71
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest (2009) 1.71
Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol (2002) 1.68
T-cell responses to CD1-presented lipid antigens in humans with Mycobacterium tuberculosis infection. Infect Immun (2003) 1.65
In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc Natl Acad Sci U S A (2007) 1.65
The diverse functions of CD1d-restricted NKT cells and their potential for immunotherapy. Immunol Lett (2005) 1.63
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother (2009) 1.63
Anthrax lethal toxin kills macrophages in a strain-specific manner by apoptosis or caspase-1-mediated necrosis. Cell Cycle (2007) 1.62
The T cell antigen receptor expressed by Valpha14i NKT cells has a unique mode of glycosphingolipid antigen recognition. Proc Natl Acad Sci U S A (2004) 1.61
Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. Proc Natl Acad Sci U S A (2009) 1.61
pH-dependent interdomain tethers of CD1b regulate its antigen capture. Immunity (2008) 1.61
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A (2008) 1.59
Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev (2002) 1.58